点击显示 收起
摘 要:目的:建立人血浆中福辛普利拉HPLC测定法,为血药浓度监测和临床合理用药提供方法学基础。方法:血浆样品酸化后用乙醚-二氯甲烷混合溶媒提取,以双氯芬酸钠为内标,流动相为甲醇-10mmol·L-1磷酸氢二钾溶液(内含5mmol·L-1氯化四丁基铵)(68:32),磷酸调Ph至7.6;流速为1.0Ml·min-1;检测波长210nm。结果:本法在10.5~1112.0ng·mL-1范围内线性良好,r=0.9988。高中低浓度的3个质控样品日内RSD<8.12%,日间RSD<8.10%,本法的相对误差<13.4%。血浆最低检测浓度为105ng·Ml-1。结论:本法快速、准确、重现性好,适用于该药物临床血药浓度监测。
HPLC Determination of Fosinoprilat--Active Metabolite of Fosinopril in Human Plasma LI Wen-yan(Shanghai
Zhabei District Central Hospital,Shanghai 200070) Abstract:Objective: To establish a HPLC assay method for the determination of fosinoprilat in human plasma. Method: A reversed phase ion - pair chromatographic method has been developed after the plasma samples having been ex tracted by ether- dichloromethane mixed solvent. Column: Hypersil ODS, 5 μm, 25 cm × 4.6 mm; Mobile phase:Methanol - 10 mmol· L-1 di - potassium hydrogen phosphate consisting of 5 mmol· L-1 tetra - butyl ammonium chloride (68:32), Ph was adjusted to 7.6 with phosphoric acid; Flow rate: 1.0 Ml·min-1; Detection wavelength: 210 nm. Results: Assay linearity was obtained in the range of 10.5 ~1112.0 ng·Ml ; intra- and inter- day precisions were lower than 8.12% and 8.10%, respectively; relative error of the method was lower than 13.4%; the lowest detectable concentration was 10.5 ng·Ml-1 Conclusion: The improved method is rapid, accurate and reproducible. It is suitable for therapeutic drug monitoring (TDM).
|
作者单位:李文艳(上海市闸北区中心医院上海
200070) 计家珠(上海市闸北区中心医院上海 200070) 吴兴文(上海市闸北区中心医院上海 200070) 舒薇(上海市闸北区中心医院上海 200070) 李文艳(上海市闸北区中心医院 上海 200070) 计家珠(上海市闸北区中心医院 上海 200070) 吴兴文(上海市闸北区中心医院 上海 200070) 舒薇(上海市闸北区中心医院 上海 200070) 参考文献: [1]Deforrest J M,
Waldron T L, Harvey C M, et al. Fosinopril, a phosphinic acid inhibitor of
angiotensin I converting enzyme: in vitro and pre - clinical in vivo
pharmacology. J Cardiovasc Pharmacol,1989, 14 (5): 730 收稿日期:2000年2月1日 出版日期:2001年3月31日 |
原载于《药物分析杂志》2001 Vol.21 No.2 P.100-103
http://search3721.sohu.com/go.phtml?coagent=sohu_go&fg=1&name=%CD%F2%B7%BD%CA%FD%BE%DD&url=http://www.wanfangdata.com.cn